PALB2
Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses
Early data on AZD5305 showed it is highly tolerable and suggested it may be amenable to combination and prevention strategies.
Genetic Testing Challenges in Oncology: Muddled Reporting, Interpretation of PALB2 VUS
A woman is sent for pancreatic cancer screening based on testing from a lab that refuses to share technical data and a doctor's misinterpretation of a VUS as pathogenic.
Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors
Tempus will screen patients sequenced through its platform for PALB2 mutations to accelerate trial enrollment.
Clovis' Rubraca Benefits BRCA1/2, PALB2-Mutated Pancreatic Cancer Patients as Maintenance Therapy
Premium
The study explored whether the PARP inhibitor benefitted patients with a wider range of mutations and pancreatic cancer subtypes than approved drugs.
Breast Cancer Risk Gene Associations Refined in Large-Scale Studies
Two new studies revealed the prevalence of pathogenic variants in breast cancer-related genes, while highlighting genes that may be most informative in the clinic.